We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb
Product News

Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb

Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb
Product News

Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb

Credit: rawpixel

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ubiquigent Limited has announced the continuation of a collaboration with Bristol Myers Squibb. The collaboration, originally between Ubiquigent and Celgene, will allow Bristol Myers Squibb to capitalize on the strength and breadth of Ubiquigent’s deubiquitylase (DUB) enzyme inhibitor drug discovery platform and expertise.

The central role of ubiquitylation in diverse cellular processes, including protein degradation, makes the enzymes responsible for ubiquitylation and de-ubiquitylation very attractive drug targets to address a range of human pathologies. Since the clinical approval of proteasome inhibitors, there has been growing interest in modulating the various components of the ubiquitylation machinery, such as DUBs, or exploiting the ubiquitin pathway via PROTACs and molecular glues to target the undruggable genome.

Ubiquigent’s Managing Director, Mr. Jason Mundin commented: “We are delighted to continue this partnership and look forward to supporting Bristol Myers Squibb in the development of novel DUB inhibitors for patients with unmet medical needs.”

Advertisement